Moxetumomab Pasudotox Poised to Answer Ongoing Questions in Hairy Cell LeukemiaOctober 26th 2019
Robert J. Kreitman, MD, discusses the role of minimal residual disease (MRD) status in hairy cell leukemia, how to effectively test for MRD, and how the combination of moxetumomab pasudotox and rituximab could alter the treatment landscape.
Can Combo of Vemurafenib and Obinutuzumab Shake Up Hairy Cell Leukemia Paradigm?October 26th 2019
The standard of care for the frontline treatment of patients with hairy cell leukemia has been purine nucleoside analogs, including pentostatin and cladribine; however, investigators are challenging this treatment in a phase II clinical trial with a targeted therapy that may provide similar benefit with fewer toxicities.
Ongoing Trial Demonstrates Promising PFS With Ibrutinib in Hairy Cell LeukemiaOctober 25th 2019
Kerry Rogers, MD, discusses the potential of ibrutinib (Imbruvica) in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field.
Dr. Kreitman on MRD-Negative CRs With Moxetumomab Pasudotox in Hairy Cell LeukemiaOctober 25th 2019
Robert J. Kreitman, MD, discusses the association between minimal residual disease-negativity and complete remission durations in patients with hairy cell leukemia treated with moxetumomab pasudotox.
Dr. Taylor on Ongoing Phase II Trial of Frontline Vemurafenib Combo in Hairy Cell LeukemiaOctober 25th 2019
Justin Taylor, MD, discusses the design of an ongoing phase II clinical trial evaluating the combination of frontline vemurafenib plus obinutuzumab in patients with hairy cell leukemia.
Dr. Rogers on Data for Ibrutinib in Hairy Cell LeukemiaOctober 25th 2019
Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.
Dr. Tiacci on Standard of Care in Hairy Cell Leukemia TreatmentOctober 25th 2019
Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell LeukemiaOctober 24th 2019
Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.